Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Ver gráficos interactivos y estados completos →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — |
| Beneficio bruto | — | — | ($16M) | ($75M) | ($9M) | ($2M) | ($1M) | ($1M) | ($1M) | — |
| % de margen bruto | — | — | — | — | — | — | — | — | — | — |
| Ingresos operativos (EBIT) | ($1.2B) | ($924M) | ($570M) | ($468M) | ($232M) | ($104M) | ($90M) | ($54M) | ($36M) | ($18M) |
| % de margen operativo | — | — | — | — | — | — | — | — | — | — |
| Ingresos netos | ($1.1B) | ($767M) | ($464M) | ($402M) | ($223M) | ($100M) | ($89M) | ($50M) | ($29M) | ($17M) |
| % de margen neto | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($1.1B) | ($742M) | ($448M) | ($392M) | ($214M) | ($97M) | ($88M) | ($49M) | ($28M) | ($17M) |
| Beneficio por acción (EPS) | $-7.64 | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 | $-3.02 | $-1.03 | $-1.15 | $-4.83 |
| Acciones en circulación (M) | 144M | 136M | 122M | 97M | 65M | 52M | 30M | 49M | — | 4M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de PCVX. /companies/us/PCVX
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms